D91FBCZ
Brachytherapy Oropharynx to None with Californium 252 (Cf-252), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 9 Ear, Nose, Mouth and Throat |
| Operation | 1 Brachytherapy |
| Body Part | F Oropharynx |
| Approach | B Low Dose Rate (LDR) |
| Device | C Californium 252 (Cf-252) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for ear, nose, mouth, and throat conditions involves placing a radioactive source directly into or next to a tumor, commonly in the oral cavity, tongue base, or nasopharynx. Because the source sits so close to the target tissue, it delivers a concentrated dose to the tumor while limiting exposure to surrounding healthy structures, which is valuable in a region crowded with nerves and tissue responsible for speech and swallowing.
The radioactive material may be temporary, removed after a set period, or permanently implanted depending on the isotope and clinical goal. This approach is often used alongside external beam radiation or surgery, particularly when a tumor recurs or when sparing normal tissue is a priority.
Anatomy & Axis Detail
Oropharynx
The oropharynx encompasses the base of tongue, tonsils, soft palate, and posterior pharyngeal wall, a region increasingly associated with HPV-related squamous cell carcinoma in addition to traditional smoking-related disease. Brachytherapy in this area is most often used as a boost to the primary tumor bed following external beam radiation and chemotherapy, delivered through interstitial needle implants placed transorally into the tongue base or tonsillar region, sometimes with image guidance to account for the irregular contours of the pharyngeal musculature. The dense concentration of swallowing and airway structures in this space means catheter placement must be planned to minimize dose to uninvolved mucosa and the contralateral side when disease is unilateral. Records should specify the oropharyngeal subsite and implant technique used.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Californium 252 (Cf-252)
Californium-252 is a neutron-emitting source rather than a gamma or beta emitter, used in specialized brachytherapy for radioresistant tumors such as certain cervical or head and neck cancers where neutrons' higher relative biological effectiveness offers an advantage. It is far less commonly used than the gamma-emitting seed isotopes and is documented separately because its neutron output changes tissue interaction and shielding requirements.
Coding & Documentation
Coders need documentation identifying the specific isotope or source used and confirming that the radioactive material was placed within or immediately adjacent to the target structure, not delivered from an external machine. The procedure note should specify whether the source is temporary or permanent, since this affects the qualifier assigned.